DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT00948168

CompletedPhase 4

Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes

6-Months Exenatide and Glucose Homeostasis Determinants in Type 2 Diabetic Patients

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

34

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI 25-40•HbA1c ≥7%

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00948168
Org study IDUCL-DIAB-01

Timeline

Milestones

Study first posted2009-07-29estimated
Last update posted2009-07-31estimated
Study start2008-07 (month precision)
Primary completion2009-07actual (month precision)
Study completion2009-07actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age40 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•type 2 diabetes subjects
•40 to 80 years
•body mass index (BMI) between 25 and 40 kg/m²
•baseline glycated haemoglobin (HbA1c) > 7.0 %, despite a maximally-tolerated combined oral therapy with a BCF stimulant (sulfonylurea or repaglinide) plus metformin

Exclusion criteria

•previous or current use of glitazone
•previous use of systemic glucocorticoids, weight-reducing drug(s) such as sibutramine
•previous exposure to GLP-1 receptor agonist or DPP-4 inhibitors

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

Improvement in HbA1c

Time frame:6 months

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint

Non-invasive modeling of glucose homeostasis determinants, including insulin sensitivity

Time frame:6 months

HOMA-IR (insulin sensitivity)

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.